Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2

被引:20
|
作者
Lu, Sheldon X. [1 ,4 ]
Fiorini, Tiago [1 ]
Lee, Jaebum [1 ]
Prasad, Hari S. [2 ]
Buxton, Amanda N. [3 ]
Bisch, Fredrick C. [4 ]
Dixon, Douglas R. [4 ]
Susin, Cristiano [1 ]
Wikesjoe, Ulf M. E. [1 ]
机构
[1] Georgia Regents Univ, LAPCR, Coll Dent Med, Augusta, GA 30912 USA
[2] Univ Minnesota, Hard Tissue Res Lab, Minneapolis, MN USA
[3] Medtron Spinal, Biol, Memphis, TN USA
[4] USA, Adv Educ Program Periodont, Ft Gordon, GA USA
关键词
biomaterials; bone; bone morphogenetic protein; osseointegration; tissue engineering; ALVEOLAR RIDGE AUGMENTATION; IMPLANT DEFECT MODEL; HISTOLOGIC OBSERVATIONS; CLINICAL-IMPLICATIONS; GRINDING TECHNIQUE; NONHUMAN-PRIMATES; TITANIUM IMPLANTS; BULKING AGENT; SPINE FUSION; BETA FAMILY;
D O I
10.1111/jcpe.12109
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background Previous studies document the therapeutic potential of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier for indications in the axial and appendicular skeleton. Nevertheless, the ACS does not comprise structural integrity to adequately support bone formation for onlay indications. The objective of this study was to evaluate local bone formation and osseointegration following surgical implantation of rhBMP-2 soak-loaded onto a compression resistant matrix (CRM). Methods Routine, contralateral, critical-size, supraalveolar, peri-implant defects in five adult male Hound Labrador mongrel dogs received 0.8mg rhBMP-2 soak-loaded onto either the ACS (benchmark control) or a CRM (collagen/-TCP/hydroxyapatite) followed by submerged wound closure for primary intention healing. The animals were euthanized at 8weeks for histologic/histometric evaluation. Results Healing was uneventful albeit considerable initial swelling was observed for either treatment. Sites receiving rhBMP-2/CRM showed significantly increased bone area (20.0 +/- 0.9 versus 12.3 +/- 2.6mm2, p=0.03) and bone density (24.1 +/- 1.4% versus 14.6 +/- 2.0%, p=0.04) compared with those receiving rhBMP-2/ACS. There were no significant differences between treatments for new bone height and osseointegration. Woven and lamellar trabecular bone lined with abundant osteoid was observed for all sites. Inconsistent cortex formation confirmed the immature nature of the newly formed bone. Seroma formation was observed for both treatments (80-100% of the animals/implants). Sites receiving rhBMP-2/CRM showed residual ceramic granules undergoing biodegradation, including accumulation of foamy macrophages. Conclusions rhBMP-2/CRM supports bone formation of clinically relevant geometry. Longer observation intervals as well as dose variations appear necessary to capture maturation of the newly formed bone, elimination of residual ceramic granules and resolution of seroma formation(s).
引用
收藏
页码:688 / 697
页数:10
相关论文
共 50 条
  • [21] Bone marrow and recombinant human bone morphogenetic protein-2 in osseous repair
    Lane, JM
    Yasko, AW
    Tomin, E
    Cole, BJ
    Waller, S
    Browne, M
    Turek, T
    Gross, J
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1999, (361) : 216 - 227
  • [22] Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion
    Glassman, SD
    Dimar, JR
    Carreon, LY
    Campbell, MJ
    Puno, RM
    Johnson, JR
    SPINE, 2005, 30 (15) : 1694 - 1698
  • [23] The effects of recombinant human bone morphogenetic protein-2, recombinant human bone morphogenetic protein-12, and adenoviral bone morphogenetic protein-12 on matrix synthesis in human annulus fibrosis and nucleus pulposus cells
    Gilbertson, Lars
    Ahn, Sang-Ho
    Teng, Pang-Ning
    Studer, Rebecca K.
    Niyibizi, Christopher
    Kang, James D.
    SPINE JOURNAL, 2008, 8 (03): : 449 - 456
  • [24] Role of Recombinant Human Bone Morphogenetic Protein-2 on Hindfoot Arthrodesis
    Hreha, Jeremy
    Krell, Ethan S.
    Bibbo, Christopher
    FOOT AND ANKLE CLINICS, 2016, 21 (04) : 793 - 802
  • [25] The concern on clinical use of recombinant human bone morphogenetic protein-2
    Wiwanitkit, Viroj
    JOURNAL OF CRANIOVERTEBRAL JUNCTION AND SPINE, 2011, 2 (02): : 102 - 103
  • [26] Effect of elcatonin on osteoinduction by recombinant human bone morphogenetic protein-2
    Okubo, Y
    Bessho, K
    Fujimura, K
    Kusumoto, K
    Ogawa, Y
    Iizuka, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 269 (02) : 317 - 321
  • [27] Sustained release emphasizing recombinant human bone morphogenetic protein-2
    Winn, SR
    Uludag, H
    Hollinger, JO
    ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (03) : 303 - 318
  • [28] Occipitocervical fusion using recombinant human bone morphogenetic protein-2
    Shahlaie, Kiarash
    Kim, Kee D.
    SPINE, 2008, 33 (21) : 2361 - 2366
  • [29] Osteogenesis by recombinant human bone morphogenetic protein-2 at skeletal sites
    Okubo, Y
    Bessho, K
    Fujimura, K
    Kusumoto, K
    Ogawa, Y
    Iizuka, T
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2000, (375) : 295 - 301
  • [30] Erratum: Enhancement of Bone Growth by Sustained Delivery of Recombinant Human Bone Morphogenetic Protein-2 in a Polymeric Matrix
    Byung Ho Woo
    Betsy F. Fink
    Richard Page
    Jay A. Schrier
    Yeong Woo Jo
    Ge Jiang
    Michelle DeLuca
    Henry C. Vasconez
    Patrick P. DeLuca
    Pharmaceutical Research, 2003, 20 : 334 - 334